



- mors with protease-activated near-infrared fluorescent probes. *Nature Biotechnol.* **17**, 375–378 (1999).
23. Tung, C.H., Mahmood, U., Bredow, S. & Weissleder, R. *In vivo* imaging of proteolytic enzyme activity using a novel molecular reporter. *Cancer Res.* **60**, 4953–4958 (2000).
 24. Marecos, E., Weissleder, R. & Bogdanov, A., Jr. Antibody-mediated versus nontargeted delivery in a human small cell lung carcinoma model. *Bioconjug. Chem.* **9**, 184–191 (1998).
 25. Seltzer, J.L. *et al.* Cleavage specificity of human skin type IV collagenase (gelatinase). Identification of cleavage sites in type I gelatin, with confirmation using synthetic peptides. *J. Biol. Chem.* **265**, 20409–20413 (1990).
 26. Niedzwiecki, L., Teahan, J., Harrison, R.K. & Stein, R.L. Substrate specificity of the human matrix metalloproteinase stromelysin and the development of continuous fluorometric assays. *Biochemistry* **31**, 12618–12623 (1992).
 27. Giambardi, T.A. *et al.* Overview of matrix metalloproteinase expression in cultured human cells. *Matrix Biol.* **16**, 483–496 (1998).
 28. Knight, C.G., Willenbrock, F. & Murphy, G. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. *FEBS Lett.* **296**, 263–266 (1992).
 29. Callahan, R.J., Bogdanov, A., Jr., Fischman, A.J., Brady, T.J. & Weissleder, R. Preclinical evaluation and Phase I clinical trial of a 99mTc-labeled synthetic polymer used in blood pool imaging. *Am. J. Roentgenol.* **171**, 137–143 (1998).
 30. Chance, B. Near-infrared images using continuous, phase-modulated, and pulsed light with quantitation of blood and blood oxygenation. *Ann. N.Y. Acad. Sci.* **838**, 29–45 (1998).
 31. Mahmood, U., Tung, C.H., Bogdanov, A., Jr. & Weissleder, R. Near-infrared optical imaging of protease activity for tumor detection. *Radiology* **213**, 866–870 (1999).
 32. Ntziachristos, V., Yodh, A.G., Schnall, M. & Chance, B. Concurrent MRI and diffuse optical tomography of breast after indocyanine green enhancement. *Proc. Natl. Acad. Sci. U.S.A.* **97**, 2767–2772 (2000).
 33. Lozonschi, L. *et al.* Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. *Cancer Res.* **59**, 1252–1258 (1999).
 34. Maekawa, R. *et al.* Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor. *Cancer Res.* **59**, 1231–1235 (1999).
 35. Ross, R. Atherosclerosis—an inflammatory disease. *N. Engl. J. Med.* **340**, 115–126 (1999).
 36. Tsukifujii, R., Tagawa, K., Hatamochi, A. & Shinkai, H. Expression of matrix metalloproteinase-1, -2 and -3 in squamous cell carcinoma and actinic keratosis. *Br. J. Cancer* **80**, 1087–1091 (1999).
 37. Plantner, J.J., Jiang, C. & Smine, A. Increase in interphotoreceptor matrix gelatinase A (MMP-2) associated with age-related macular degeneration. *Exp. Eye Res.* **67**, 637–645 (1998).
 38. Holskin, B.P. *et al.* A continuous fluorescence-based assay of human cytomegalovirus protease using a peptide substrate. *Anal. Biochem.* **227**, 148–155 (1995).
 39. Ishiguro, N., Ito, T., Miyazaki, K. & Iwata, H. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, and glycosaminoglycans in synovial fluid from patients with rheumatoid arthritis. *J. Rheumatol.* **26**, 34–40 (1999).
 40. Giraudon, P., Buart, S., Bernard, A. & Belin, M.F. Cytokines secreted by glial cells infected with HTLV-I modulate the expression of matrix metalloproteinases (MMPs) and their natural inhibitor (TIMPs): Possible involvement in neurodegenerative processes. *Mol. Psychiatry* **2**, 107–110, 184 (1997).
 41. Tung, C.H., Bredow, S., Mahmood, U. & Weissleder, R. Preparation of a cathepsin D sensitive near-infrared fluorescence probe for imaging. *Bioconjug. Chem.* **10**, 892–896 (1999).
 42. Brown, P.D., Levy, A.T., Margulies, I.M., Liotta, L.A. & Stetler-Stevenson, W.G. Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines. *Cancer Res.* **50**, 6184–6191 (1990).
 43. Collier, I.E. *et al.* H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. *J. Biol. Chem.* **263**, 6579–6587 (1988).

ON THE MARKET

GEL BOXES

C.B.S. Scientific offers a line of color-coded horizontal gel systems designed to help differentiate use by specific labs or for specific purposes. Available in five fluorescent colors, these Mini-Gel or Midi-Gel systems feature tapered baffles for leak-proof gel formation, UV-transparent gel beds, and safety covers with attached power leads. The horizontal mini-gel system is offered with a gel bed size of either 5.5 x 8.5 cm or 7.5 x 10 cm. Both sizes accommodate several different comb thicknesses and formats. As little as 2 µl of sample is required per sample well, says the company. Three sizes of the midi-gel system are available: 10.5 x 11 cm, 14 x 10 cm and 14 x 16 cm. They are suitable for use with a variety of polycarbonate or Teflon-coated aluminum combs.

Tel. (+1) 858-755-4959

www.cbsscientific.com

CHROMATOGRAPHY COLUMNS


Dionex introduces the ProPac WAX-10 (weak anion exchange) and SAX-10 (strong anion exchange) columns for high-resolution analysis of proteins with small differences in charge and structure. ProPac resin uses a surface-controlled polymerization technology. The packing substrate is a highly crosslinked core (which makes the packing solvent-compatible) grafted with a neutral, hydrophilic layer to eliminate hydrophobic interactions with proteins. This

layer is then grafted with a polymer layer of controlled thickness that contains the anion-exchange functional group (tertiary amine for the WAX-10 and quaternary ammonium for the SAX-10). These columns are said to have a moderate capacity and are stable over a pH range of 2–10. They are suitable for characterization and quality-control assays of closely related protein variants, including acidic proteins, phosphorylated proteins, glycosylated protein variants and sialylated proteins.

Tel. (+1) 408-737-0700

www.dionex.com

ASSORTED KITS AND REAGENTS



Cytochrome c ELISA

A new ELISA kit for the quantitative detection of human cytochrome c in cell culture lysates, human whole blood or serum is now offered by Bender MedSystems. This ELISA provides researchers with a new tool for detecting the activation of apoptotic programs in cells. Recent research involving serum from patients with hematological malignancies indicates that serum-cytochrome c monitoring might also serve as a clinical

marker that indicates the onset of apoptosis and cell turnover *in vivo*.

Tel. (+43) 1-796-4040-0

www.bendermedsystems.com

A DNA fragmentation kit based on the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) method has been added to Clontech's ApoAlert line of apoptosis detection products. The ApoAlert DNA fragmentation assay kit is based on the direct incorporation of fluorescein-dUTP at the free 3'-hydroxyl ends of DNA fragments produced during apoptosis. Direct incorporation of the fluorescein tag is designed to save time and reduce nonspecific background. The assay can be performed on cultured cells, as well as formalin-fixed, paraffin-embedded tissue sections.

Tel. (+1) 415-424-8222

www.clontech.com

A new brochure from Alexis Biochemicals outlines almost a dozen new products for apoptosis research. Among the highlighted apoptosis detection products are antibodies and antisera to Smac/DIABLO, FLIP, BAFF, TACI and BCMA. Also featured are TRAIL receptor pathway products, including the new KillerTRAIL and monoclonal antibody to TRAIL, as well as other popular soluble TRAIL, TRAIL receptors and antibodies.

Tel. (+1) 858-658-0065

www.alexis-corp.com